Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:5074
Name high grade ependymoma
Definition A high grade glioma that is derived from ependymal cells, a type of glial cell, located_in ventricle lining within the central part of the brain.
Source DiseaseOntology.org
Alt Ids DOID:0060107
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma high grade ependymoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Terminated USA 0
NCT01795313 Phase 0 HLA-A2 restricted synthetic peptide vaccine + Imiquimod Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod Recruiting USA 0
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Completed USA 0
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Completed USA 0
NCT02502708 Phase I Indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Completed USA 0
NCT02774421 Phase I Sargramostim + Trastuzumab Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma Recruiting USA 0
NCT03095248 Phase II Selumetinib Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601) Completed USA 0
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Completed USA | SWE | POL | NOR | NLD | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS 2
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting USA 0
NCT03220646 Phase II Abemaciclib Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors Active, not recruiting USA 0
NCT03387020 Phase I Ribociclib Everolimus + Ribociclib Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Completed USA 0
NCT03585465 Phase Ib/II Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Active, not recruiting FRA | BEL 0
NCT03652545 Phase I MultiTAA-specific T cells Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) Recruiting USA 0
NCT03911388 Phase I HSV-1 G207 HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Active, not recruiting USA 0
NCT04049669 Phase II Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Recruiting USA 0
NCT04541082 Phase I ONC206 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Recruiting USA 0
NCT04743661 Phase II Bevacizumab + Irinotecan + Omburtamab I-131 + Temozolomide Omburtamab I-131 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Active, not recruiting USA 0
NCT06161519 Phase Ib/II PLX038 PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications Recruiting USA 0
NCT06466798 Phase I Methotrexate + Nivolumab Azacitidine + Nivolumab Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Recruiting USA 0
NCT06639607 Phase Ib/II Nivolumab + PEP-CMV + Temozolomide PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) Not yet recruiting USA 0